Bert Andersson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1416678/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet, The, 2014, 384, 2235-2243.	13.7	475
2	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 2018, 39, 26-35.	2.2	426
3	Heart Rate and Rhythm and the BenefitÂofÂBeta-Blockers in PatientsÂWithÂHeart Failure. Journal of the American College of Cardiology, 2017, 69, 2885-2896.	2.8	198
4	Changes in Early and Late Diastolic Filling Patterns Induced by Long-term Adrenergic β-Blockade in Patients With Idiopathic Dilated Cardiomyopathy. Circulation, 1996, 94, 673-682.	1.6	79
5	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. European Heart Journal, 2015, 36, 1106-1114.	2.2	53
6	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the <scp>MAGGIC</scp> metaâ€analysis. European Journal of Heart Failure, 2015, 17, 1182-1191.	7.1	48
7	Angiotensinâ€II type 1 receptor gene polymorphism and longâ€ŧerm survival in patients with idiopathic congestive heart failure. European Journal of Heart Failure, 1999, 1, 363-369.	7.1	46
8	Impact of Renal Impairment on Beta-Blocker Efficacy in PatientsÂWithÂHeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2893-2904.	2.8	39
9	CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy. JACC: Heart Failure, 2019, 7, 878-887.	4.1	37
10	Optimizing the Management of Heart Failure With Preserved Ejection Fraction in the Elderly by Targeting Comorbidities (OPTIMIZE-HFPEF). Journal of Cardiac Failure, 2016, 22, 539-544.	1.7	25
11	Coronary flow reserve in patients with resistant hypertension. Clinical Research in Cardiology, 2017, 106, 151-157.	3.3	25
12	Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study. Transplantation, 2020, 104, 154-164.	1.0	25
13	Parvovirus B19 in Endomyocardial Biopsy of Patients With Idiopathic Dilated Cardiomyopathy: Foe or Bystander?. Journal of Cardiac Failure, 2019, 25, 60-63.	1.7	21
14	Massive parallel sequencing questions the pathogenic role of missense variants in dilated cardiomyopathy. International Journal of Cardiology, 2017, 228, 742-748.	1.7	16
15	Continuous improvement in outcome after heart transplantation — Long-term follow-up after three decades of experience. International Journal of Cardiology, 2017, 231, 188-194.	1.7	15
16	The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial. European Heart Journal, 2018, 39, 3464-3471.	2.2	14
17	Factors influencing long-term heart failure mortality in patients with obstructive hypertrophic cardiomyopathy in Western Sweden: probable dose-related protection from beta-blocker therapy. Open Heart, 2019, 6, e000963.	2.3	14
18	Temporal improvement in heart failure survival related to the use of a nurse-directed clinic and recommended pharmacological treatment. International Journal of Cardiology, 2005, 104, 257-263.	1.7	13

Bert Andersson

#	Article	IF	CITATIONS
19	The effects of baroreflex activation therapy on blood pressure and sympathetic function in patients with refractory hypertension: the rationale and design of the Nordic BAT study*. Blood Pressure, 2017, 26, 294-302.	1.5	13
20	Hypertension is associated with increased mortality in patients with ischaemic heart disease after revascularization with percutaneous coronary intervention – a report from SCAAR. Blood Pressure, 2017, 26, 166-173.	1.5	11
21	Cardiac arrest in Wilson's disease after curative liver transplantation: a lifeâ€threatening complication of myocardial copper excess?. ESC Heart Failure, 2019, 6, 228-231.	3.1	10
22	Short atrioventricular delay pacing therapy in young and old patients with hypertrophic obstructive cardiomyopathy: good long-term results and a low need for reinterventions. Europace, 2018, 20, 1683-1691.	1.7	8
23	Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients—a SCHEDULE trial substudy. Transplant International, 2020, 33, 517-528.	1.6	4
24	Early post-transplant elevated pulmonary artery pressure predicts adverse outcome in cardiac recipients. IJC Heart and Vasculature, 2020, 26, 100438.	1.1	3
25	Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients. ESC Heart Failure, 2020, 7, 567-576.	3.1	2
26	Morbidity and resource usage after myectomy- or pacing-treatment in hypertrophic obstructive cardiomyopathy: A case-control study. International Journal of Cardiology, 2021, 322, 197-203.	1.7	2